BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21638284)

  • 21. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
    Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
    Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic polymorphisms of orosomucoid on the Han population in Nanjing of China.
    Li JH; Xu JQ; Li Y; Zhuang YY; Gong JB
    Clin Chim Acta; 1999 Oct; 288(1-2):161-8. PubMed ID: 10529468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distal promoter regions are responsible for differential regulation of human orosomucoid-1 and -2 gene expression and acute phase responses.
    Sai K; Kurose K; Koizumi T; Katori N; Sawada J; Matsumura Y; Saijo N; Yamamoto N; Tamura T; Okuda H; Saito Y
    Biol Pharm Bull; 2014; 37(1):164-8. PubMed ID: 24389491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic polymorphisms of orosomucoid ORM1 and ORM2 in a Japanese population: occurrence of new ORM1 alleles.
    Sebetan IM; Sagisaka K
    Z Rechtsmed; 1989; 102(1):5-9. PubMed ID: 2922958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
    Sai K; Saito Y; Fukushima-Uesaka H; Kurose K; Kaniwa N; Kamatani N; Shirao K; Yamamoto N; Hamaguchi T; Kunitoh H; Ohe Y; Tamura T; Yamada Y; Minami H; Ohtsu A; Yoshida T; Saijo N; Sawada J
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):529-37. PubMed ID: 17992531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orosomucoid phenotyping with monoclonal antibodies:polymorphic occurrence of ORM1*Q0 in aboriginal Taiwanese populations.
    Umetsu K; Yuasa I; Harada A; Suzuki T; Pan IH; Ishida T; Saitou N; Horai S
    Hum Hered; 1995; 45(4):181-5. PubMed ID: 7558048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-1-acid glycoprotein.
    Fournier T; Medjoubi-N N; Porquet D
    Biochim Biophys Acta; 2000 Oct; 1482(1-2):157-71. PubMed ID: 11058758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
    Colombo S; Buclin T; Décosterd LA; Telenti A; Furrer H; Lee BL; Biollaz J; Eap CB;
    Clin Pharmacol Ther; 2006 Oct; 80(4):307-18. PubMed ID: 17015049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study Analysis.
    Li LY; Guo Y; Gonzalez M; Ouellet D
    J Clin Pharmacol; 2020 Mar; 60(3):391-399. PubMed ID: 31602692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
    Tsushima T; Kasai H; Tanigawara Y
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of surgery and chronic disease states on the concentrations and phenotype distribution of α1-acid glycoprotein: studies in patients with breast cancer and patients with chronic inflammatory disease.
    Hanada K; Yamanaka E; Yamamoto N; Minami H; Kawai S; Sasaki Y; Ogata H
    Int J Clin Pharmacol Ther; 2011 Jul; 49(7):415-21. PubMed ID: 21726491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics.
    Huang Z; Ung T
    Curr Drug Metab; 2013 Feb; 14(2):226-38. PubMed ID: 23092311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pig α1-acid glycoprotein: characterization and first description in any species as a negative acute phase protein.
    Heegaard PM; Miller I; Sorensen NS; Soerensen KE; Skovgaard K
    PLoS One; 2013; 8(7):e68110. PubMed ID: 23844161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Up-regulation by clarithromycin of alpha(1)-acid glycoprotein expression in liver and primary cultured hepatocytes.
    Komori T; Kai H; Shimoishi K; Kabu K; Nonaka A; Maruyama T; Tamura K; Otagiri M
    Biochem Pharmacol; 2001 Nov; 62(10):1391-7. PubMed ID: 11709199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hepatic orosomucoid/α1-acid glycoprotein gene cluster is regulated by the nuclear bile acid receptor FXR.
    Porez G; Gross B; Prawitt J; Gheeraert C; Berrabah W; Alexandre J; Staels B; Lefebvre P
    Endocrinology; 2013 Oct; 154(10):3690-701. PubMed ID: 23861371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel.
    Yin T; Cai H; Liu J; Cui B; Wang L; Yin L; Zhou J; Huo M
    Eur J Pharm Sci; 2016 Feb; 83():79-87. PubMed ID: 26699227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.
    Nakajima Y; Yoshitani T; Fukushima-Uesaka H; Saito Y; Kaniwa N; Kurose K; Ozawa S; Aoyagi N; Kamatani N; Yamamoto N; Kunitoh H; Ohe Y; Tamura T; Yoshida T; Minami H; Saijo N; Katori N; Sawada J
    Clin Pharmacol Ther; 2006 Aug; 80(2):179-91. PubMed ID: 16890579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine.
    Li JH; Xu JQ; Cao XM; Ni L; Li Y; Zhuang YY; Gong JB
    Clin Chim Acta; 2002 Mar; 317(1-2):85-92. PubMed ID: 11814462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: improved pharmacokinetics and biodistribution in tumor-bearing mice.
    Wang X; Deng L; Chen X; Pei H; Cai L; Zhao X; Wei Y; Chen L
    J Pharm Sci; 2011 Mar; 100(3):1196-205. PubMed ID: 20860011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Orosomucoid 1 protein is involved in the vitamin D - mediated macrophage de-activation process.
    Gemelli C; Martello A; Montanari M; Zanocco Marani T; Salsi V; Zappavigna V; Parenti S; Vignudelli T; Selmi T; Ferrari S; Grande A
    Exp Cell Res; 2013 Dec; 319(20):3201-13. PubMed ID: 23973664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.